Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics’ Chief Financial Officer Louis Edward Tamayo reported a mix of stock grant and related share sale. On June 29, 2026, he received an award of 12,000 shares of common stock at no cost as compensation.
On July 1, 2026, he sold 4,641 shares of common stock at a weighted average price of $4.49 per share. A footnote explains this sale was made to cover tax obligations on the release of performance Restricted Stock Units (RSUs), meaning it was a tax-related disposition rather than a discretionary portfolio sale.
Following these transactions, he directly holds 97,024 shares of common stock, which include 89,665 RSUs. Each RSU represents a contingent right to receive one share of Lexeo common stock in the future, typically upon meeting vesting conditions.
Lexeo Therapeutics, Inc. chief operating officer Jose Manuel Otero reported two equity transactions in company common stock. On June 29, he received 12,060 shares at no cost as a grant or award, increasing his direct holdings. On July 1, he sold 4,666 shares at a weighted average price of $4.48 per share to cover tax obligations related to the release of performance Restricted Stock Units, according to the footnotes. After these transactions, he directly holds 137,482 shares, which include 100,621 RSUs, indicating the sale represents a small portion of his overall position.
Lexeo Therapeutics Chief Medical Officer Narinder Pal Bhalla reported a compensation-related stock grant and a tax-related share sale. On June 29, 2026, he received 55,000 shares of common stock as a grant or award. On July 1, 2026, 22,306 shares of common stock were sold at a weighted average price of $4.42 per share to cover tax obligations on the release of performance Restricted Stock Units. After these transactions, he directly held 82,194 shares of common stock, including 49,500 RSUs, each representing a contingent right to receive one share.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan Townsend reported two equity transactions involving the company’s common stock. He received a grant of 67,000 shares of common stock on June 29, 2026 at no cost as a compensation-related award. On July 1, 2026, he sold 25,947 shares at a weighted average price of $4.48 per share, with prices ranging from $4.3402 to $4.7507, specifically to cover tax obligations tied to the release of performance restricted stock units. After the sale, he directly owned 377,817 shares of common stock, which includes 252,130 restricted stock units, indicating he retains a substantial equity position in the company.
LXEO files a Form 144 notice regarding proposed sales of Common Stock. The excerpt lists 4,666 shares in a "Securities To Be Sold" row dated 07/01/2026 and references a Restricted Stock Vesting event on 06/29/2026 tied to compensation. The filing names Fidelity Brokerage Services LLC as a broker/holder.
LXEO director files a Form 144 proposing resale of common stock. The notice lists 25,947 shares in connection with restricted stock vesting on 06/29/2026. The filing also records 3,342 shares sold on 05/18/2026 for $16,926.90.
Lexeo Therapeutics, Inc. reported results from its 2026 Annual Meeting of Stockholders held virtually on June 25, 2026. Stockholders elected three Class III directors—R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley—to serve until the 2029 annual meeting.
Support for the director nominees ranged from 48,792,570 to 64,731,479 votes in favor, with broker non-votes of 9,955,777 on each director. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,497,386 votes for, 55,579 against, and 30,099 abstentions.
Lexeo Therapeutics director Steven Altschuler received a grant of options covering 35,000 shares of Common Stock. The stock options have an exercise price of $4.70 per share and expire on June 24, 2036. All 35,000 underlying shares vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as he remains in continuous service. Following this award, he holds 35,000 stock options directly, and the transaction reflects a compensation-related grant rather than an open-market purchase.